Cancer information / Diagnosis and treatment / Chemotherapy and other drug therapies / Bisphosphonates / Potential side effects

Brown, J. P., Josse, R. G., & The Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. (2004, August 26). Canadian Medical Association Journal. (Revised Edition). Ottawa: Canadian Medical Association. 167(10): pp. S1-S34.

Cancer Care Ontario. Drug Formulary. Toronto, ON: Cancer Care Ontario.

Cancerbackup. (2005, 01/03). Bisphosphonates. (Reviewed Edition). London, UK: Cancerbackup.

Fisch, M. J., and Cleeland, C. S. Managing cancer pain. Skeel, R. T., (Ed.). (2003). Handbook of Cancer Chemotherapy. (6th Edition). Philadelphia: Lippincott Williams & Wilkins. 31: pp. 650-673.

Lavoie Smith, E. Cancer pain. Varricchio, C., Pierce, M., Hinds, P. S., & Ades, T. B. (2004). Cancer Source Book for Nurses. (8th Edition). Sudbury, MA: Jones and Bartlett Publishers. 23: pp. 349-360.

Melo, M. D., & Obeid, G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. (2005, February). Journal of the Canadian Dental Association. Ottawa: Canadian Dental Association (CDA). 71(2): pp. 111-113a.

National Cancer Institute. (2005, 02/17). Pain (PDQ®): Health Professional Version. Bethesda: National Cancer Institute.

Wooltorton, E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. (2005, 06/21). Canadian Medical Association Journal. Ottawa: Canadian Medical Association. 172(13): p. 1684.